Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results
Oncternal Therapeutics (Nasdaq: ONCT) announced it will release its second quarter 2021 financial results on August 5, 2021, post-market. A management webcast will follow at 2:00 p.m. PT to discuss results and provide a business update. The company is advancing oncology therapies addressing unmet medical needs, with a pipeline including cirmtuzumab and TK216, undergoing various clinical trials for cancers such as mantle cell lymphoma and Ewing sarcoma.
- Cirmtuzumab is in multiple clinical trials for various cancers, showing strong pipeline activity.
- The company focuses on unmet medical needs in oncology, which may lead to significant market opportunities.
- No specific financial data or results are provided ahead of the earnings report, causing uncertainty.
- The company is still in the clinical stage with no commercial products yet available.
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2021 financial results after the U.S. financial markets close on Thursday, August 5, 2021. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a comprehensive business update and discuss the Company’s financial results.
The live webcast of the call will be available online via a link from the “Investor Relations” page of the Company’s website at www.oncternal.com, and the call will be archived there for at least 30 days.
About Oncternal Therapeutics
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The clinical pipeline includes cirmtuzumab, an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) and in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer, as well as a Phase 2 clinical trial of cirmtuzumab in combination with venetoclax, a Bcl-2 inhibitor, in patients with relapsed/refractory CLL. Oncternal is also developing a chimeric antigen receptor T cell (CAR-T) therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. The clinical pipeline also includes TK216, an investigational targeted small-molecule inhibitor of the ETS family of oncoproteins, that is being evaluated in a Phase 1/2 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. More information is available at https://oncternal.com/.
Oncternal Contacts:
Company Contact
Richard Vincent
858-434-1113
rvincent@oncternal.com
Investor Contact
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com
FAQ
When will Oncternal report its Q2 2021 financial results?
What time is the Oncternal management webcast?
What is Oncternal's focus in drug development?
What clinical trials is Oncternal conducting?
